Literature DB >> 10458979

Immunity to Candida albicans: Th1, Th2 cells and beyond.

L Romani1.   

Abstract

Resistance to Candida albicans infection in mice results from the development of T helper (Th) type 1 cell responses. Cytokines produced by Th1 cells activate macrophages and neutrophils to a candidacidal state. The development of Th2 responses underlines susceptibility to infection, because cytokines produced by Th2 cells inhibit Th1 development and deactivate phagocytic effector cells. With the recognition of the reciprocal influences between innate and adaptive Th immunity, it appears that the coordinated action of these two lines of immune defense is required to efficiently oppose the infectivity of the fungus and to determine its lifelong commensalism at the mucosal level.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10458979     DOI: 10.1016/S1369-5274(99)80064-2

Source DB:  PubMed          Journal:  Curr Opin Microbiol        ISSN: 1369-5274            Impact factor:   7.934


  51 in total

1.  Primary role for CD4(+) T lymphocytes in recovery from oropharyngeal candidiasis.

Authors:  C S Farah; S Elahi; K Drysdale; G Pang; T Gotjamanos; G J Seymour; R L Clancy; R B Ashman
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

2.  Cytokine gene polymorphisms and the outcome of invasive candidiasis: a prospective cohort study.

Authors:  Melissa D Johnson; Theo S Plantinga; Esther van de Vosse; Digna R Velez Edwards; P Brian Smith; Barbara D Alexander; John C Yang; Dennis Kremer; Gregory M Laird; Marije Oosting; Leo A B Joosten; Jos W M van der Meer; Jaap T van Dissel; Thomas J Walsh; John R Perfect; Bart-Jan Kullberg; William K Scott; Mihai G Netea
Journal:  Clin Infect Dis       Date:  2011-12-05       Impact factor: 9.079

Review 3.  Epithelial cells and innate antifungal defense.

Authors:  G Weindl; J Wagener; M Schaller
Journal:  J Dent Res       Date:  2010-04-15       Impact factor: 6.116

4.  Comparison of pathogenesis and host immune responses to Candida glabrata and Candida albicans in systemically infected immunocompetent mice.

Authors:  J Brieland; D Essig; C Jackson; D Frank; D Loebenberg; F Menzel; B Arnold; B DiDomenico; R Hare
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

Review 5.  Immunology of dermatophytosis.

Authors:  Sandro Rogerio Almeida
Journal:  Mycopathologia       Date:  2008-05-14       Impact factor: 2.574

6.  Macrophage-mediated responses to Candida albicans in mice expressing the human immunodeficiency virus type 1 transgene.

Authors:  Mathieu Goupil; Emilie Bélanger Trudelle; Véronique Dugas; Catherine Racicot-Bergeron; Francine Aumont; Serge Sénéchal; Zaher Hanna; Paul Jolicoeur; Louis de Repentigny
Journal:  Infect Immun       Date:  2009-06-29       Impact factor: 3.441

7.  Anti-Aspergillus human host defence relies on type 1 T helper (Th1), rather than type 17 T helper (Th17), cellular immunity.

Authors:  Louis Y A Chai; Frank van de Veerdonk; Renoud J Marijnissen; Shih-Chin Cheng; Ai Leng Khoo; Magda Hectors; Katrien Lagrou; Alieke G Vonk; Johan Maertens; Leo A B Joosten; Bart-Jan Kullberg; Mihai G Netea
Journal:  Immunology       Date:  2009-12-02       Impact factor: 7.397

8.  Characterization of prostaglandin E2 production by Candida albicans.

Authors:  John R Erb-Downward; Mairi C Noverr
Journal:  Infect Immun       Date:  2007-04-30       Impact factor: 3.441

9.  Dysregulated inflammatory response to Candida albicans in a C5-deficient mouse strain.

Authors:  Alaka Mullick; Miria Elias; Serge Picard; Lucie Bourget; Orce Jovcevski; Susan Gauthier; Ashleigh Tuite; Penelope Harakidas; Craig Bihun; Bernard Massie; Philippe Gros
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

10.  Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated Candidiasis in recipients of a Candida albicans vaccine.

Authors:  Carla Bromuro; Antonella Torosantucci; Paola Chiani; Stefania Conti; Luciano Polonelli; Antonio Cassone
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.